Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-016283
Filing Date
2020-08-19
Accepted
2020-08-19 14:43:35
Documents
66
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 678897
2 ex31-1.htm EX-31.1 15516
3 ex32-1.htm EX-32.1 7764
  Complete submission text file 0001493152-20-016283.txt   4298313

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE endv-20200630.xml EX-101.INS 669016
5 XBRL SCHEMA FILE endv-20200630.xsd EX-101.SCH 66184
6 XBRL CALCULATION FILE endv-20200630_cal.xml EX-101.CAL 53814
7 XBRL DEFINITION FILE endv-20200630_def.xml EX-101.DEF 230229
8 XBRL LABEL FILE endv-20200630_lab.xml EX-101.LAB 422446
9 XBRL PRESENTATION FILE endv-20200630_pre.xml EX-101.PRE 305649
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

EIN.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 201116752
SIC: 2834 Pharmaceutical Preparations